Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
Clinical trial NCT05849610 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05849610
- Sponsor
- PETHEMA Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-21
- Primary completion
- 2026-03-03
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.